scholarly article | Q13442814 |
P2093 | author name string | Petros Efthimiou | |
Bella Mehta | |||
Sabeeda Kadavath | |||
P2860 | cites work | Adult-onset Still's disease | Q80354973 |
Leflunomide and methotrexate combination in refractory adult-onset Still's disease | Q80400099 | ||
Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset Still's disease: the first case report | Q81238130 | ||
Adult-onset Still's disease | Q82285530 | ||
Pulmonary hypertension in systemic sclerosis | Q82294311 | ||
Macrophage activation syndrome associated with etanercept in a child with systemic onset juvenile idiopathic arthritis | Q82530778 | ||
Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids | Q82950882 | ||
Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series | Q83084990 | ||
Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab | Q83274923 | ||
Macrophage activation syndrome treated with anakinra | Q83975572 | ||
Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease | Q24681558 | ||
Adult-onset Still's disease with disseminated intravascular coagulation and multiple organ dysfunctions dramatically treated with cyclosporine A | Q28167268 | ||
Adult-onset Still disease presenting with disseminated intravascular coagulation | Q28168791 | ||
Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura | Q28214974 | ||
Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders | Q28362327 | ||
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial | Q28374317 | ||
Chronic relapsing thrombotic thrombocytopenic purpura in adult onset Still's disease | Q33346657 | ||
Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. | Q33359709 | ||
Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. A 10-year experience at a single institution | Q33364030 | ||
Reactive haemophagocytic syndrome in adult-onset Still's disease: a report of six patients and a review of the literature | Q33370577 | ||
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome and adult onset Still's disease: case report and review of the literature | Q33379355 | ||
Thrombotic thrombocytopenic purpura and adult onset Still's disease | Q33383879 | ||
Thrombotic microangiopathy and purtscher-like retinopathy associated with adult-onset Still's disease: a role for glomerular vascular endothelial growth factor? | Q33386885 | ||
Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab | Q33388583 | ||
A case of adult-onset Still's disease complicated by thrombotic thrombocytopenic purpura with retinal microangiopathy and rapidly fatal cerebral edema | Q33401390 | ||
Enhanced plasminogen-activator production by leukocytes in the human and murine Chediak-Higashi syndrome | Q33460119 | ||
Anti-CD36 antibodies in thrombotic thrombocytopenic purpura | Q33488104 | ||
Cyclosporine therapy of adult onset Still's disease with disseminated intravascular coagulation | Q33494769 | ||
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome | Q33504463 | ||
Treatment of pulmonary hypertension secondary to connective tissue diseases. | Q33634193 | ||
Pulmonary involvement in adult-onset Still's disease | Q33719785 | ||
Adult-onset Still's disease. Clinical course and outcome | Q34191960 | ||
Preliminary criteria for classification of adult Still's disease | Q34405573 | ||
Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy? | Q34632947 | ||
Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis | Q34646212 | ||
Liver abnormalities in rheumatic diseases | Q35040109 | ||
Retrospective monocentric study of 17 patients with adult Still's disease, with special focus on liver abnormalities. | Q35082963 | ||
Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences | Q35579173 | ||
Diagnosis and management of adult onset Still's disease | Q35637158 | ||
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. | Q35637949 | ||
Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions | Q35724900 | ||
Drug-induced diffuse alveolar hemorrhage syndromes and vasculitis | Q35737068 | ||
Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome | Q35847631 | ||
Diffuse alveolar hemorrhage | Q35872280 | ||
Interleukin-6: from basic science to medicine--40 years in immunology | Q36072403 | ||
Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis | Q36116060 | ||
Pulmonary Arterial Hypertension in Adult-Onset Still's Disease: Rapid Response to Anakinra. | Q36220786 | ||
Pathogenesis and management of adult-onset Still's disease | Q36583909 | ||
Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study | Q36633190 | ||
Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. | Q36855193 | ||
Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances | Q37079113 | ||
A case of adult-onset Still's disease complicated with diffuse alveolar hemorrhage. | Q37116890 | ||
Adult-onset Still disease | Q37333091 | ||
Adult Still's disease: manifestations, disease course, and outcome in 62 patients | Q37670649 | ||
An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. | Q37834144 | ||
The use of Canakinumab, a novel IL-1β long-acting inhibitor, in refractory adult-onset Still's disease | Q38003501 | ||
Biological treatment in adult-onset Still's disease | Q38049762 | ||
Adult onset Still's disease: experience in 23 patients and literature review with emphasis on organ failure | Q39667880 | ||
Adult Still's disease: review of 228 cases from the literature | Q39694157 | ||
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis | Q40263864 | ||
Adult-Onset Still's Disease Masquerading as Sepsis in an Asplenic Active Duty Soldier | Q40263935 | ||
Relapsing macrophage activating syndrome in a 15-year-old girl with Still's disease: a case report | Q40369117 | ||
Fatal myocarditis in adult-onset Still disease with diffuse intravascular coagulation. | Q40403433 | ||
A case of macrophage activation syndrome successfully treated with anakinra | Q40408368 | ||
Etanercept as a rescue agent in patient with adult onset Still's disease complicated with congestive heart failure. | Q40418487 | ||
Adult onset Still's disease: a study of 14 cases | Q40441853 | ||
Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. | Q40455988 | ||
Hemophagocytic syndrome in one patient with adult-onset Still's disease. Presentation with febrile neutropenia | Q40483423 | ||
Acute respiratory failure revealing adult-onset Still's disease: diagnostic value of low glycosylated ferritin level | Q40494122 | ||
Rapid responses to anakinra in patients with refractory adult-onset Still's disease | Q40507008 | ||
Macrophage activation syndrome associated with systemic juvenile idiopathic arthritis | Q40518260 | ||
Clinical manifestations, disease course, and complications of adult-onset Still's disease in Taiwan | Q40520885 | ||
Disseminated intravascular coagulation in a case of adult onset Still's disease | Q40643502 | ||
A case of hemophagocytic syndrome with severe liver injury manifestating adult Still's disease | Q40644635 | ||
A case of adult onset Still's disease complicated with adult respiratory distress syndrome and disseminated intravascular coagulation | Q40687328 | ||
A case of adult Still's disease with pulmonary hypertension | Q40765056 | ||
Interleukin-6 in biology and medicine | Q40850225 | ||
Adult Still's disease | Q40860971 | ||
Comparison of long term evolution of adult onset and juvenile onset Still's disease, both followed up for more than 10 years | Q41221844 | ||
Successful treatment of refractory adult onset Still's disease with rituximab | Q42955722 | ||
Which patients stop working because of RA? | Q43050973 | ||
Guidelines for the diagnosis and treatment of pulmonary hypertension | Q43141520 | ||
Non-infectious mitral endocarditis during Still's disease in adults. A case with histologic study of the endocardium | Q44134375 | ||
Efficacy of thalidomide in refractory adult Still's disease: a new case report | Q44441205 | ||
Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease | Q44554787 | ||
Worsening of macrophage activation syndrome in a patient with adult onset Still's disease after initiation of etanercept therapy | Q44924027 | ||
Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. | Q45012569 | ||
Leflunomide and azathioprine combination in refractory adult-onset Still's disease | Q45291859 | ||
Macrophage activation syndrome: a frequent but under-diagnosed complication associated with rheumatic diseases | Q46732683 | ||
Sildenafil for pulmonary arterial hypertension associated with connective tissue disease | Q46912711 | ||
Macrophage activation syndrome and etanercept in children with systemic juvenile rheumatoid arthritis | Q48012891 | ||
Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. | Q50672047 | ||
Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome | Q51545663 | ||
Pulmonary arterial hypertension in autoimmune diseases: an analysis of 19 cases from a medical center in northern Taiwan. | Q51811224 | ||
Pulmonary hypertension in collagen vascular disease | Q57824393 | ||
[Adult onset Still's disease revealed by a myocarditis] | Q64039734 | ||
Pulmonary arterial hypertension complicating adult-onset Still's disease | Q64043572 | ||
The biology of interleukin-6 | Q69086773 | ||
[Still's disease in adults with disseminated intravascular coagulation] | Q70152170 | ||
Chronic liver disease and Still's disease | Q70365127 | ||
Fulminant hepatic failure in adult onset Still's disease | Q71322293 | ||
Liver transplant in adult Still's disease | Q73789431 | ||
Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease | Q78667433 | ||
Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis | Q78874963 | ||
Cardiac tamponade: a life-threatening complication of Still's disease | Q79235218 | ||
The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis | Q79844555 | ||
Pulmonary hypertension in a patient with adult-onset Stills disease | Q80001180 | ||
P433 | issue | 3 | |
P921 | main subject | adult-onset Still's disease | Q1187697 |
P304 | page(s) | 305-314 | |
P577 | publication date | 2014-01-17 | |
P1433 | published in | Clinical Rheumatology | Q15754927 |
P1476 | title | Life-threatening complications of adult-onset Still's disease | |
P478 | volume | 33 |
Q92482917 | Acquired Amegakaryocytic Thrombocytopenia in Adult-onset Still's Disease: Successful Combination Therapy with Tocilizumab and Cyclosporine |
Q28079446 | Adult-onset Still's disease: current challenges and future prospects |
Q36208563 | Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers |
Q38637780 | Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? |
Q90550872 | Are the 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome applicable to patients with adult-onset Still's disease? |
Q48362160 | Clinical and histopathological features of cutaneous manifestations of adult-onset Still disease. |
Q38530013 | Clinical features and correct diagnosis of macrophage activation syndrome. |
Q55109011 | Diagnostic and management of life-threatening Adult-Onset Still Disease: a French nationwide multicenter study and systematic literature review. |
Q40630580 | Epidemiological study of adult-onset Still's disease using a Japanese administrative database |
Q47727637 | H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome. |
Q64039508 | Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response |
Q48340351 | Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. |
Q64235820 | Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study |
Q57143910 | Mechanisms, biomarkers and targets for adult-onset Still's disease |
Q34042413 | Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart. |
Q26830024 | Pathophysiology, subtypes, and treatments of adult-onset Still's disease: An update |
Q38463009 | Presentation and diagnosis of adult-onset Still's disease: the implications of current and emerging markers in overcoming the diagnostic challenge. |
Q97653199 | Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations |
Q37053491 | Pulmonary arterial hypertension secondary to adult-onset Still's disease: Response to cyclosporine and sildenafil over 15 years of follow-up |
Q47160193 | Refractory Adult Onset Still’s Disease |
Q50352247 | Severe Pulmonary Hypertension Due to Adult-Onset Still's Disease. |
Q38925320 | The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review |
Q39445471 | Tocilizumab for uncontrollable systemic inflammatory response syndrome complicating adult-onset Still disease: Case report and review of literature |
Q34043097 | Treatment of adult-onset Still's disease: a review |
Q38679486 | Treatment of adult-onset still's disease: up to date. |
Q42240996 | Unusual manifestations and unusual mimics of adult onset Still's disease. |